Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10763
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHerbertson, R Aen
dc.contributor.authorScarsbrook, A Fen
dc.contributor.authorLee, S Ten
dc.contributor.authorTebbutt, Niall Cen
dc.contributor.authorScott, Andrew Men
dc.date.accessioned2015-05-16T00:18:52Z
dc.date.available2015-05-16T00:18:52Z
dc.date.issued2008-10-23en
dc.identifier.citationClinical Radiology 2008; 64(3): 225-37en
dc.identifier.govdoc19185652en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10763en
dc.description.abstractPositron-emission tomography-computed tomography (PET/CT) is rapidly being integrated into the imaging pathways of several different tumour types, most frequently using the glucose analogue 2- [(18)F]-fluoro-2-deoxy-D-glucose (FDG). Integrated FDG-PET/CT combines functional and anatomical imaging to improve sensitivity and specificity of tumour detection. The aim of this article is to review the established, emerging, and future roles of FDG-PET/CT in the management of patients with colorectal cancer (CRC).en
dc.language.isoenen
dc.subject.otherColonoscopyen
dc.subject.otherColorectal Neoplasms.drug therapy.radionuclide imagingen
dc.subject.otherCost-Benefit Analysisen
dc.subject.otherFluorodeoxyglucose F18.diagnostic useen
dc.subject.otherGreat Britainen
dc.subject.otherHumansen
dc.subject.otherNeoplasm Recurrence, Local.radionuclide imagingen
dc.subject.otherNeoplasm Stagingen
dc.subject.otherNeoplasm, Residualen
dc.subject.otherPositron-Emission Tomography.economics.methods.trendsen
dc.subject.otherRadiopharmaceuticals.diagnostic useen
dc.subject.otherRadiotherapy Planning, Computer-Assisteden
dc.subject.otherSensitivity and Specificityen
dc.subject.otherTomography, X-Ray Computed.economics.methods.trendsen
dc.titleEstablished, emerging and future roles of PET/CT in the management of colorectal cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical radiologyen
dc.identifier.affiliationrebecca.herbertson@ludwig.edu.auen
dc.identifier.affiliationLudwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1016/j.crad.2008.08.008en
dc.description.pages225-37en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/19185652en
dc.type.austinJournal Articleen
local.name.researcherScott, Andrew M
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

50
checked on Dec 21, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.